Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors (eg, olaparib) are effective against BRCA-mutated cancers at/near maximum tolerated doses by trapping PARP-1 on damaged chromatin, benefitting only small patient proportions. The benefits of targeting non-DNA repair aspects of PARP with metro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghonim, Mohamed A, Ibba, Salome V, Tarhuni, Abdelmetalab F, Errami, Youssef, Luu, Hanh H, Dean, Matthew J, El-Bahrawy, Ali H, Wyczechowska, Dorota, Benslimane, Ilyes A, Del Valle, Luis, Al-Khami, Amir A, Ochoa, Augusto C, Boulares, A Hamid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839867/
https://www.ncbi.nlm.nih.gov/pubmed/33495297
http://dx.doi.org/10.1136/jitc-2020-001643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839867/
https://www.ncbi.nlm.nih.gov/pubmed/33495297
http://dx.doi.org/10.1136/jitc-2020-001643

Ejemplares similares